Patent EP0396387A2 successfully refreshed from Google Patents.
EP0396387A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
A novel antibody delivery system for biological response modifiers
Assignee: Research Development Foundation
•
Filing: 1990-05-01
•
Granted: —
•
Expires: 2010-05-01
Abstract
Abstract The present invention provides a novel conjugate of an antibody with a biological response modifiers; delivery system which delivers biological response modifiers to target tissues and cells. The present invention also provides a method for treating diseases by administering antibody-biological response modifier conjugates. For example, a monoclonal antibody conjugated to a lymphokine or cytokine, such as for example, TNF.
Inventors
- 👤 Michael G. Rosenblum
- 👤 Clyde William Wellen
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-05 18:08
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/395; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6835; A61K47/6851; A61P; A61P27/00; A61P27/02; A61P35/00
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
22 words
A composition of matter comprising a conjugate of an antibody directed toward a tumor associated antigen and a biological response modifier moiety.
Claim 2
Dependent Claim
22 words
A composition of matter comprising a conjugate of an antibody directed toward a tumor associated antigen and a biological response modifier moiety.
Claim 3
Dependent Claim
22 words
The composition of claim 1 wherein said composition is a recombinantly produced compound comprising an antibody moiety and a biological response modifier.
Claim 4
Dependent Claim
10 words
The composition of claim 1 wherein said moiety is cytotoxic.
Claim 5
Dependent Claim
30 words
The composition of claim 1 wherein said moiety is selected from the group consisting of tumor necrosis factor, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, TNF-α, TNF-β, IFN-α, IFN-β, IFNλ.
Claim 6
Dependent Claim
12 words
The composition of claim 1 wherein said moiety is tumor necrosis factor.
Claim 7
Dependent Claim
15 words
The composition of claim 1, wherein said antibody is directed toward a breast carcinoma antigen.
Claim 8
Dependent Claim
14 words
The composition of claim 6 wherein said antibody has the characteristics of 15A8 antibody.
Claim 9
Dependent Claim
14 words
The composition of claim 1, wherein said antibody is directed toward a melanoma antigen.
Claim 10
Dependent Claim
14 words
The composition of claim 8 wherein said antibody has the characteristics of ZME-018 antibody.
Claim 11
Dependent Claim
24 words
A composition comprising a conjugate of an antibody directed toward a tumor associated antigen and a biological response modifier moiety and a human interferon.
Claim 12
Dependent Claim
24 words
A composition comprising a conjugate of an antibody directed toward a tumor associated antigen and a biological response modifier moiety and a human interferon.
Claim 13
Dependent Claim
38 words
The composition of claim 1 wherein said conjugate is a gene-fusion product recombinantly produced by fusion of a gene coding for the antigen recognition site of a monoclonal antibody with a gene coding for a biological response modifier.
Claim 14
Dependent Claim
20 words
The composition of claim 12 wherein said biological response modifiers are selected from the group consisting of lymphokines and cytokines.
Claim 15
Dependent Claim
14 words
The composition of claim 12 wherein said biological response modifier is tumor necrosis factor.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.